United States

Astellas Pharma Inc (4503.T)

4503.T on Tokyo Stock Exchange

20 Mar 2018
Change (% chg)

¥-14 (-0.90%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Latest Key Developments (Source: Significant Developments)

Astellas Pharma to retire treasury shares
Wednesday, 26 Apr 2017 11:23pm EDT 

April 27 (Reuters) - Astellas Pharma Inc <4503.T>:* Says it will retire 85 million shares( 4 percent of outstanding ) of its common stock on May 31.* Says the total shares outstanding is 2.07 billion shares after the retirement.  Full Article

Astellas Pharma to acquire Ogeda SA
Sunday, 2 Apr 2017 07:30pm EDT 

Astellas Pharma Inc <4503.T>: under agreement, Astellas has agreed to pay up to a total of eur 800 million . Astellas will make an initial payment of eur 500 million in consideration of 100% of equity in Ogeda at closing of transaction . Ogeda shareholders will be eligible to receive additional eur 300 million with attainment of certain milestones for fezolinetant .Astellas is still reviewing impact of this transaction on its financial forecasts for fiscal year ending March 31, 2018.  Full Article

RIBOMIC plans joint research agreement with Astellas pharma
Tuesday, 21 Mar 2017 02:30am EDT 

RIBOMIC Inc <4591.T> :Says it plans to enter into joint research agreement with Astellas pharma Inc <4503.T>, regarding R&D of aptamers pharmaceuticals.  Full Article

X-Chem signs broad drug discovery collaboration with Astellas Pharma
Monday, 20 Mar 2017 08:15am EDT 

X-Chem Inc: X-Chem Inc - announced signing of a broad drug discovery collaboration with Astellas Pharma Inc . X-Chem Inc - under terms of this multi-year agreement, X-Chem will receive an up-front payment of $16 million . X-Chem Inc - as per agreement, co is eligible to receive research funding, as well as license and option fees as drug discovery collaboration proceeds . X-Chem - additionally, Astellas has option to license compounds identified through the collaboration . X-Chem - co will be entitled to pre-clinical, developmental, and commercial milestone payments on licensed compounds against each target .X-Chem - milestone payments could amount to over $100 million per target, in addition to royalties based on sales of future products.  Full Article

Astellas and Affinivax announce worldwide partnership for maps vaccine targeting pneumococcal disease
Tuesday, 28 Feb 2017 12:20am EST 

Astellaas Pharma Inc <4503.T>: Says Affinivax, Inc. and Astellas Pharma Inc. entered into an exclusive worldwide license agreement to develop and commercialize a vaccine targeting Streptococcus pneumoniae .Says the partnership will utilize Affinivax’s proprietary vaccine technology platform – Multiple Antigen Presenting System (MAPS) – to advance a novel MAPS vaccine targeted to prevent and reduce the spread of pneumococcal disease.  Full Article

Lupin's unit Kyowa and Astellas enter into agreement
Monday, 27 Feb 2017 01:17am EST 

Lupin Ltd : Says Astellas and Lupin s subsidiary Kyowa enter into an agreement . Says deal gives Kyowa the exclusive right to distribute and promote extended-release tablets of quetiapine fumarate in Japan .When astellas gets approval for new drug application of extended-release tablets of quetiapine fumarate, Kyowa will exclusively distribute products in Japan.  Full Article

Astellas and Ironwood report positive top-line results from phase III Linaclotide trial in Japan
Sunday, 29 Jan 2017 07:00pm EST 

Astellas Pharma Inc <4503.T>: Astellas and Ironwood report positive top-line results from phase III Linaclotide trial for patients with chronic constipation conducted in Japan . Says Linaclotide is approved in Japan as first prescription treatment for adults with irritable bowel syndrome with constipation . Says patients in phase III cc trial in Japan continue to receive open-label Linaclotide for an additional 52 weeks . Astellas Pharma -top-line trial results indicate that linaclotide-treated patients showed statistically significant improvement compared to placebo-treated patients .Says most common adverse event reported in this trial was diarrhea.  Full Article

Astellas terminates agreement with UMN Pharma for cell culture based influenza vaccine programs
Tuesday, 10 Jan 2017 03:07am EST 

Astellas Pharma Inc <4503.T> :Says co terminates agreement with UMN Pharma Inc <4585.T> , for the co-development and Astellas’ exclusive commercialization of ASP7374 and ASP7373, the cell culture based influenza vaccine programs in Japan.  Full Article

Astellas Pharma acquires Ganymed Pharmaceuticals AG
Tuesday, 20 Dec 2016 09:06pm EST 

Astellas Pharma Inc <4503.T>:Says it acquired Germany-based biopharmaceutical firm Ganymed Pharmaceuticals AG.  Full Article

Astellas announces FDA fast track designation for its DNA vaccine
Tuesday, 20 Dec 2016 08:00am EST 

Astellas Pharma Inc <4503.T>: Astellas Pharma - phase I clinical trial to evaluate safety, tolerability, immune response of ASP0892 in adults allergic to peanuts has been initiated .Astellas announces FDA fast track designation for ASP0892, DNA vaccine for mitigation of severe hypersensitivity reactions due to peanut allergy.  Full Article

BRIEF-U.S. FDA Grants Priority Review For Supplemental New Drug Application For Xtandi